Chronic Infection Research Tops SPT Week in Review

5. FDA Grants Breakthrough Designation to Pembrolizumab, Lenvatinib Combo for Unresectable Liver Cancer

If approved, pembrolizumab in combination with lenvatinib will be indicated for the first-line treatment of advanced unresectable hepatocellular carcinoma. Read more.

4. FDA OKs Pfizer's Rituximab Biosimilar

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis. Read more.

3. FDA Grants Priority Review to Tazemetostat for Epithelioid Sarcoma

If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. Read more.

2. Gene Therapy Receives Rare Pediatric Disease Designation for Methylmalonic Acidemia

There are currently no approved therapies for methylmalonic acidemia, a rare and life-threatening disease caused by mutations in the MUT gene. Read more.

1. Chronic Infection Research Expected to Spark Specialty Pharmacy Growth

Scientific advances could lead to earlier prevention and treatment of infection, helping to avoid irreversible or severe chronic diseases. Read more.